Pharmacogenomics of CYP2D6: molecular genetics, interethnic differences and clinical importance.
about
Impact of CYP2D*6 in the adjuvant treatment of breast cancer patients with tamoxifenDistribution of CYP2D6 alleles and phenotypes in the Brazilian populationMolecular Dynamics Simulations to Investigate the Influences of Amino Acid Mutations on Protein Three-Dimensional Structures of Cytochrome P450 2D6.1, 2, 10, 14A, 51, and 62Liver Function Test Abnormalities in Depressed Patients Treated with Antidepressants: A Real-World Systematic Observational Study in Psychiatric SettingsVariation in Human Cytochrome P-450 Drug-Metabolism Genes: A Gateway to the Understanding of Plasmodium vivax RelapsesEffects of CYP2D6 and CYP3A5 polymorphisms on tamoxifen and its metabolites in Thai breast cancer patients.CYP2D6 Phenotyping Using Urine, Plasma, and Saliva Metabolic Ratios to Assess the Impact of CYP2D6∗10 on Interindividual Variation in a Chinese PopulationAfrican Americans with cancer pain are more likely to receive an analgesic with toxic metabolite despite clinical risks: a mediation analysis study.SNP genotyping using TaqMan technology: the CYP2D6*17 assay conundrum.Utilizing structures of CYP2D6 and BACE1 complexes to reduce risk of drug-drug interactions with a novel series of centrally efficacious BACE1 inhibitors.Detection of an endogenous urinary biomarker associated with CYP2D6 activity using global metabolomicsPolymorphism at 19q13.41 Predicts Breast Cancer Survival Specifically after Endocrine Therapy.CYP2D6 Haplotype Determination Using Long Range Allele-Specific Amplification: Resolution of a Complex Genotype and a Discordant Genotype Involving the CYP2D6*59 Allele.CYP2D6 copy number distribution in the US population.CYP2D7 Sequence Variation Interferes with TaqMan CYP2D6 (*) 15 and (*) 35 Genotyping.Influence of CYP2D6 polymorphisms on serum levels of tamoxifen metabolites in Spanish women with breast cancerAtomoxetine: A Review of Its Pharmacokinetics and Pharmacogenomics Relative to Drug Disposition.Role of cytochrome P450 2D6 genetic polymorphism in carvedilol hydroxylation in vitroFactors affecting the development of adverse drug reactions to β-blockers in hospitalized cardiac patient populationPrevalence of CYP2D6*2, CYP2D6*4, CYP2D6*10, and CYP3A5*3 in Thai breast cancer patients undergoing tamoxifen treatment.Investigation of CYP2D6 Gene Polymorphisms in Turkish PopulationIdiosyncratic Drug-Induced Liver Injury (IDILI): Potential Mechanisms and Predictive Assays.Distribution of genetic polymorphisms of genes encoding drug metabolizing enzymes & drug transporters - a review with Indian perspective.Pharmacogenomics and adverse drug reactions in children.Pharmacogenomics can improve antipsychotic treatment in schizophrenia.Complexities of CYP2D6 gene analysis and interpretation.African variation at Cytochrome P450 genes: Evolutionary aspects and the implications for the treatment of infectious diseases.Pharmacogenomics of methadone maintenance treatment.Interethnic variability of CYP2D6 alleles and of predicted and measured metabolic phenotypes across world populations.Biotransformation of xenobiotics in the human colon and rectum and its association with colorectal cancer.Asunaprevir: A Review of Preclinical and Clinical Pharmacokinetics and Drug-Drug Interactions.Asunaprevir (BMS-650032) for the treatment of hepatitis C virus.Genetic Variants of Cytochrome CYP2D6 in Two Mixed Chilean Populations.MicroRNA hsa-miR-370-3p suppresses the expression and induction of CYP2D6 by facilitating mRNA degradation.Impact of CYP2D6 genotype on amitriptyline efficacy for the treatment of diabetic peripheral neuropathy: a pilot study.Personalized medicine: Genetic risk prediction of drug response.Quantification of the steady-state plasma concentrations of clozapine and N-desmethylclozapine in Japanese patients with schizophrenia using a novel HPLC method and the effects of CYPs and ABC transporters polymorphisms.Proteome-wide analyses of human hepatocytes during differentiation and dedifferentiationDrug Metabolism in Preclinical Drug Development: A Survey of the Discovery Process, Toxicology, and Computational Tools.The impact of CYP2D6 polymorphisms on the pharmacokinetics of codeine and its metabolites in Mongolian Chinese subjects.
P2860
Q27026180-D14331C6-3733-493A-B81B-465B1159C801Q28543940-B64792E4-E5C5-4BCB-A5FD-34F2D1540DABQ28551168-58DB958A-A3C8-4703-AAAD-15D6E7CD143CQ28552027-5B869ED0-D16C-4B33-80DE-F706930E057AQ28553162-0A68E786-131B-4149-B171-41191E131F03Q33589336-0372B563-A6F9-4E65-B2B7-4CF5244280E1Q33621987-A6CB6C7F-E266-436C-AF7A-30774F6C22F2Q34091251-20C2E085-7DB7-445A-B222-A78CF2C8A0B8Q35193678-CA05B817-4D6A-464A-87B6-D0F9370D929EQ35558099-E047A812-D355-4414-AC9B-8B8F99DAF899Q35800807-B660179C-5998-497A-9125-A451296A734BQ36071595-BE7BC674-FF77-4DE5-86B6-2578C21AE45BQ36240653-F02ECC58-88B0-4F10-BB9A-9945CDB00280Q36440207-AE52EEC5-DEAD-47DC-9F25-647CA7DCAB6FQ36454174-848CF513-DBA3-4DFC-83F3-0A41766C289BQ36909858-439A2272-1F7D-43AC-9482-7CAF17E3A1F5Q36925745-8C192997-0850-4798-B712-537734D8D8F5Q37003594-BD5CDC09-2685-4F03-8103-C441A1770799Q37158873-B44A7FF0-2676-47B7-8269-6D13BC700A70Q37170578-B634B12C-19F0-48C9-8F2E-AB7CD7FD8997Q37299922-5C59CB4D-2573-4355-B291-5E6D28D65362Q37590883-27BB7B41-780F-4C5D-894F-2245C7A4590FQ37715233-6AAD5433-4FA4-4F0B-8738-F5C5543E49C5Q37719025-68B48A46-4246-45CB-8CCA-A49C64CE6B9BQ38100731-92A61ED9-334C-4972-A257-37FE7F752820Q38154914-89639190-7403-49D4-81FE-2FC56D46E50FQ38183664-57A7D7E3-B8FB-4033-B43B-786831283B72Q38222510-36034F04-5A12-4A79-8713-C0A8782205FFQ38260323-2574C3B4-F250-4AFC-9A3F-446EFEFB66F6Q38357424-621FF941-D341-4B26-8AD4-08D3573EE92AQ38547705-7800739C-3FA6-4A1E-9FF0-5FE57F89CF52Q38594613-848BC38A-8D22-40F9-A22A-CE871A15DB3AQ38669777-C6F8DA53-6F9C-409C-A10B-BAF20773A1DEQ38701992-784491F8-81FC-4077-AC16-B7F6733DF8A2Q38738593-DC4B8490-B4A2-4926-AF87-3E6275E37B8DQ38756015-F2B85C23-9390-4DA1-B348-B31624323D94Q39117848-969AD001-C07B-431E-8EFA-2CC7C852F59DQ39176204-03502E28-4704-44C2-BE80-382AB9619832Q39182452-C8D94783-C583-4F8D-B966-A55BCF5F0E21Q39219864-03BB8ECD-93AD-407D-BDBD-791C23DD2243
P2860
Pharmacogenomics of CYP2D6: molecular genetics, interethnic differences and clinical importance.
description
2011 nî lūn-bûn
@nan
2011 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Pharmacogenomics of CYP2D6: mo ...... ences and clinical importance.
@ast
Pharmacogenomics of CYP2D6: mo ...... ences and clinical importance.
@en
Pharmacogenomics of CYP2D6: mo ...... ences and clinical importance.
@nl
type
label
Pharmacogenomics of CYP2D6: mo ...... ences and clinical importance.
@ast
Pharmacogenomics of CYP2D6: mo ...... ences and clinical importance.
@en
Pharmacogenomics of CYP2D6: mo ...... ences and clinical importance.
@nl
prefLabel
Pharmacogenomics of CYP2D6: mo ...... ences and clinical importance.
@ast
Pharmacogenomics of CYP2D6: mo ...... ences and clinical importance.
@en
Pharmacogenomics of CYP2D6: mo ...... ences and clinical importance.
@nl
P1476
Pharmacogenomics of CYP2D6: mo ...... ences and clinical importance.
@en
P2093
Lay Kek Teh
P356
10.2133/DMPK.DMPK-11-RV-121
P577
2011-12-20T00:00:00Z